# Clinical Benefits of Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma
## 3 HAIC Versus SORafenib  
### Clinical Response and Outcomes  
As mentioned earlier, no RCTs have compared HAIC with sorafenib in a large number of patients with advanced HCC. A few retrospective studies have compared HAIC with sorafenib as well as one RCT with a small population [11; 12; 13; 14; 15; 16; 17] (Table 2). The previous prospective and retrospective studies showed that the overall survival (OS) and response rate of HAIC were significantly higher than those of sorafenib in HCC patients with vascular invasion [12; 14; 15; 16], and other studies indicated that the progression-free survival of HAIC was better than that of sorafenib [13; 17]. However, these studies had small sample sizes. A recent retrospective cohort study with a large population (2006 patients: 541 patients with HAIC; 1465 patients with sorafenib) demonstrated that the MST of patients with vascular invasion without EHM was significantly longer in the HAIC group than in the sorafenib group (10.1 versus 9.1 months) after propensity score matching, although no significant difference in OS was observed between both groups in patients without both vascular invasion and EHM after propensity score matching (12.2 and 15.4 months for the HAIC and sorafenib groups, respectively) [11]. Similarly, a meta-analysis indicated that HAIC is superior to sorafenib in HCC patients with vascular invasion [35]. Furthermore, \begin{table}
\begin{tabular}{c c c c c c c} \hline \hline
**Authors [Reference]** & **Publishing Year** & **Regimens** & **Case Number** & \begin{tabular}{c} **Vascular** \\ **Invasion (\%)** \\ \end{tabular} & \
\begin{tabular}{c} **Response** \\ **Rate (\%)** \\ \end{tabular} &
\begin{tabular}{c} **Median Survival** \\ **Time (Months)** \\ \end{tabular} \\ \hline \hline \multirow{4}{*}{[PERSON], et al. [22]} & \multirow{4}{*}{2015} & Low-dose FP & \multirow{4}{*}{90} & \multirow{4}{*}{ND} & \multirow{4}{*}{34.4} & \multirow{4}{*}{10.6} \\  & & including the combination of & & & & \\  & & LV/IV or IV & & & & \\  & & plus IFN & & & & \\ \hline \multirow{2}{*}{[PERSON], et al. [23]} & \multirow{2}{*}{2013} & \multirow{2}{*}{CODP+5 FU} & \multirow{2}{*}{476} & \multirow{2}{*}{44.1} & \multirow{2}{*}{40.5} & \multirow{2}{*}{14.0} \\  & & & & & & (341 patients) \\ \hline \multirow{2}{*}{[PERSON], et al. [24]} & \multirow{2}{*}{2010} & Low-dose FP & \multirow{2}{*}{52} & \multirow{2}{*}{80.8} & \multirow{2}{*}{38.5} & \multirow{2}{*}{15.9} \\  & & & & & & \\ \hline \hline \multirow{4}{*}{[PERSON], et al. [25]} & \multirow{2}{*}{2012} & IFNa, 5-FU & \multirow{2}{*}{34} & \multirow{2}{*}{90.0} & \multirow{2}{*}{26.7} & \multirow{2}{*}{8.4} \\  & & Low-dose & & & & \\  & & FP/CDDP & & & & \\ \hline \multirow{2}{*}{[PERSON], et al. [26]} & \multirow{2}{*}{2011} & IFNa, CDDP, & \multirow{2}{*}{57} & \multirow{2}{*}{26.7} & \multirow{2}{*}{45.6} & \multirow{2}{*}{17.6} \\  & & IFNa, 5-FU & & & & \\ \hline \hline \multirow{2}{*}{[PERSON], et al. [27]} & \multirow{2}{*}{2011} & IFNa, 5-FU & \multirow{2}{*}{102} & \multirow{2}{*}{100.0} & \multirow{2}{*}{39.2} & \multirow{2}{*}{9.0} \\  & & & & & & \\ \hline \hline \multirow{2}{*}{[PERSON], et al. [28]} & \multirow{2}{*}{2006} & IFNa, 5-FU & \multirow{2}{*}{116} & \multirow{2}{*}{100.0} & \multirow{2}{*}{52.0} & \multirow{2}{*}{6.9} \\  & & & & & & \\ \hline \hline \multirow{2}{*}{[PERSON], et al. [29]} & \multirow{2}{*}{2013} & CDDP powder & \multirow{2}{*}{25} & \multirow{2}{*}{100.0} & \multirow{2}{*}{28.0} & \multirow{2}{*}{7.6} \\  & & (IA call) & & & & \\ \hline \hline \multirow{2}{*}{[PERSON], et al. [30]} & \multirow{2}{*}{2011} & CDDP & \multirow{2}{*}{41} & \multirow{2}{*}{83.3} & \multirow{2}{*}{12.2} & \multirow{2}{*}{7.5} \\  & & CDDP, 5-FU & & & & \\ \hline \hline \multirow{2}{*}{[PERSON], et al. [31]} & \multirow{2}{*}{2008} & CDDP powder & \multirow{2}{*}{80} & \multirow{2}{*}{27.5} & \multirow{2}{*}{33.8} & ND \\  & & & & & \\ \hline \hline \end{tabular}
\end{table} 
Table 1: Regimens of hepatic arterial infusion chemotherapy. [PERSON] et al.